AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

More Images
NORTH CHICAGO, Ill.—AbbVie Inc. (NYSE: ABBV) has extended the expiration date of the offers to exchange any and all outstanding notes of certain series issued by Allergan Finance, Allergan Inc., Allergan Sales and Allergan Funding SCS for new notes to be issued by AbbVie, according to an announcement on Monday. The extension also covers the related consent solicitations being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures governing the Allergan notes. The transactions are related to AbbVie’s proposed offer to acquire Allergan.

As VMAIL reported in June 2019, AbbVie and Allergan have entered into a transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction valued at approximately $63 billion ($80 billion including debt).

In its announcement on Monday, AbbVie said it has extended the expiration date from 5:00 p.m. (EDT) on Friday, April 10 until 5:00 p.m. (EDT) on April 24 (as the same may be further extended).

On the early participation date of Nov. 7, 2019, requisite consents were received and supplemental indentures were executed eliminating substantially all of the covenants, restrictive provisions, events of default and any guarantees of the related Allergan notes in each Allergan indenture, the announcement noted. Such supplemental indentures will become operative only upon settlement of the exchange offers.